-
Cernostics’ Work Complements VP Biden’s “Moonshot to Cure Cancer” Phila. Announcement
Cernostics, Inc., Bethlehem, has developed a diagnostic and prognostic test that predicts the risk of developing esophageal cancer. Esophageal cancer is among the most deadly cancers, with a five-year survival rate of less than 17%. Driven by increasing rates of gastroesophageal reflux disease (GERD), it is also the fastest-growing cancer by incidence in western countries. Continue Reading…
Daily Archives:
January 14th, 2016
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.